ClinicalTrials.gg
CompletedNCT04238195Updated Mar 13, 2020

A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects

A Phase 1 interventional study of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo and Moxifloxacin 400mg in TQT Study, sponsored by Spero Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-13.

Sponsored by Spero Therapeutics · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2020, 6 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a randomized, double-blind (with respect to Tebipenem pivoxil hydrobromide [TBPM-PI-HBr]/placebo only), placebo- and active-control, single-dose, 4-way crossover study that will enroll 24 healthy adult male and female subjects. There will be a washout period of at least 7 days between dosing in each period and each subject will receive all 4 treatments over 4 periods in a crossover study design.

Read the detailed description

This is a randomized, double-blind (with respect to TBPM-PI-HBr / placebo only), placebo- and active-control, single-dose, 4-way crossover study. Twenty-four (24) healthy, adult, male and female subjects will be enrolled. Screening of subjects will occur within 28 days prior to the first dosing.

All subjects will receive a single dose of 4 different study treatments over 4 separate treatment periods, each separated by a 7-day washout period.

On Day 1 of Period 1, subjects will be randomized to 1 of 12 treatment sequences. Sentinel group: In Period 1 only, 4 subjects will be dosed 24 hours prior to the remaining 20 subjects. Each of the 4 subjects from the sentinel group will receive a different treatment.

On Day 1 of each period, subjects will receive a single oral therapeutic dose of TBPM-PI-HBr (Treatment A), supratherapeutic dose of TBPM-PI-HBr (Treatment B), placebo (Treatment C), or moxifloxacin (Treatment D) according to the randomization scheme.

In each period, cardiodynamic ECGs and PK blood samples will be collected pre-dose and for 24 hours post-dose. Safety will be monitored throughout the study by repeated clinical and laboratory evaluations.

Discontinued subjects who have received study drug will not be replaced.

02

Conditions studied

  • TQT Study

Keywords

  • TQT
03

In context

Lead sponsor

Spero Therapeutics is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 3 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must fulfill all of the following inclusion criteria to be eligible for participation in the study:

  1. Healthy, adult, male or female, 18-65 years of age, inclusive, at screening.
  2. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study, based on subject self- reporting.
  3. (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at screening.
  4. Medically healthy with no medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.
  5. No clinically significant history or presence of findings as judged by the PI or qualified designee at screening and prior to dosing of Period 1, including each criterion as listed below:

    1. Normal sinus rhythm (heart rate between 50 and 100 bpm, inclusive);
    2. interval (Fridericia's correction to the QT interval) ≤ 450 msec;
    3. QRS interval \< 110 msec;
    4. PR interval \< 220 msec.
  6. For a female of : either be sexually inactive (abstinent as a lifestyle) for 3 months prior to the first dosing and throughout the study or be using one of the following acceptable methods:

    • non-hormone releasing intrauterine device for at least 3 months prior to the first dosing and throughout the study.
    • surgical sterilization of the partner (vasectomy for 4 months minimum prior to the first dosing. In addition, female subjects of childbearing potential will be advised to remain sexually inactive or to keep the same birth control method for at least 28 days following the last dose.
  7. For a female of non-childbearing potential: must have undergone one of the following sterilization procedures at least 6 months prior to the first dosing:

    • hysteroscopic sterilization (with confirmation of procedure success with hystosalpingogram);
    • bilateral tubal ligation or bilateral salpingectomy;
    • hysterectomy;
    • bilateral oophorectomy;

    or be with amenorrhea for at least 1 year prior to the first dosing and have follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status.

  8. A non-vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days after the last dosing.

    (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to the first dosing of study drug. A male who has been vasectomized less than 4 months prior to study first dosing must follow the same restrictions as a non-vasectomized male).

  9. If male, must agree not to donate sperm from the first dosing until 90 days after the last dosing.
  10. Understands the study procedures in the form (ICF), and be willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

Subjects must not be enrolled in the study if they meet any of the following criteria:

  1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  2. History or presence of medical or psychiatric condition or disease in the opinion of the PI or designee.
  3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  4. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
  5. History or presence of or idiosyncratic reaction to the study drug(s) or related compounds (especially fluoroquinolone-, carbapenem-, penicillin-, and cephalosporin-antibiotics sensitivity).
  6. History or presence of any of the following, deemed clinically significant by the PI or designee:

    1. Ventricular pre-excitation syndrome (Wolff-Parkinson White syndrome);
    2. Arrhythmia or history of arrhythmia requiring medical intervention;
    3. Risk factors for Torsade de Pointes (e.g., heart failure, cardiomyopathy, or family history of Long Syndrome);
    4. Sick sinus syndrome, second or third degree atrioventricular block, myocardial infarction, pulmonary congestion, symptomatic or significant cardiac arrhythmia, prolonged QTcF interval, or conduction abnormalities.
  7. Allergy to electrode adhesive patches, band aids, adhesive dressing or medical tape.
  8. History of epilepsy or seizure disorder.
  9. History of known genetic metabolism anomaly associated with carnitine deficiency (e.g., carnitine transporter defect, methylmalonic aciduria, propionic acidemia).
  10. Female subjects with a positive pregnancy test or who are lactating.
  11. Positive urine drug or alcohol results at screening or first check-in.
  12. Positive results at screening for (HIV), surface antigen (HBsAg) or virus (HCV).
  13. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
  14. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
  15. Estimated \<80 mL/min at screening.
  16. Unable to refrain from or anticipates the use of the following drugs beginning 14 days prior to the first dosing and throughout the study:

    • Any drug, including prescription and non-prescription medications , herbal remedies, or vitamin supplements. After first dosing, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the PI or designee.
    • Any gastric acid-reducing medications, including but not limited to proton pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole), histamine-2 receptor antagonists (e.g., nizatidine, famotidine, cimetidine, ranitidine), and antacids (e.g., Alka-Seltzer, Milk of Magnesia, Amphojel, Gelusil, Maalox, Mylanta, Rolaids, Pepto-Bismol).
    • Valproic acid or divalproex sodium.
    • Probenecid.
  17. Has been on a diet incompatible with the on-study diet, in the opinion of the PI or designee, within the 30 days prior to the first dosing and throughout the study.
  18. Donation of blood or significant blood loss within 56 days prior to the first dosing.
  19. Plasma donation within 7 days prior to the first dosing.
  20. Participation in another clinical study within 30 days prior to the first dosing. The 30- day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment A

    600 mg TBPM-PI-HBr (2 x 300 mg tablets) and TBPM-PI-HBr-matching placebo (2 x matching placebo tablets) administered at Hour 0 on Day 1.

    Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo · Other: Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)

  • Experimental
    Treatment B

    1200 mg TBPM-PI-HBr (4 x 300 mg tablets) administered at Hour 0 on Day 1.

    Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)

  • Placebo comparator
    Treatment C

    TBPM-PI-HBr-matching placebo (4 x matching placebo tablets) administered at Hour 0 on Day 1.

    Other: Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)

  • Other
    Treatment D

    Positive Control - unblinded: 400 mg moxifloxacin (1 x 400 mg tablet) administered at Hour 0 on Day 1.

    Drug: Moxifloxacin 400mg

Interventions

  • DrugTebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo

    Drug page: Tebipenem

    Treatment A: Subjects receive TBPM-PI-HBr + matching Placebo.

    Also known as: SPR994

  • Treatment D: Subjects receive 1 400 mg tablet of moxifloxacin administered in an open label manner.

    Also known as: Avelox

  • OtherPlacebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)

    Treatment C: Subjects receive TBPM-PI-HBr matching placebo.

  • Treatment B: Subjects receive TBPM-PI-HBr.

    Also known as: SPR994

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr on the heart rate corrected QT interval (QTc) by assessing concentration-QT (C-QT) relationship using exposure-response modeling.

    Holter monitors will be used to collect continuous 12-lead electrocardiogram (ECG) data on Day 1. Triplicate 10-second, 12-lead ECG recordings will be extracted from the Holter monitor data within a 5-minute time window prior to the pharmacokinetic (PK) blood samples collected as close to the exact time point as possible

    Time frame: Pre-dose through 24 hours post-dose

Secondary outcomes

  1. 1. To evaluate the effect of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr on other electrocardiogram (ECG) parameters.

    Number of participants with changes in QTc from baseline.

    Time frame: Pre-dose through 24 hours post-dose

  2. 1. To evaluate the effect of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr on other electrocardiogram (ECG) parameters.

    Number of participants with changes in QT from baseline.

    Time frame: Pre-dose through 24 hours post-dose

  3. 1. To evaluate the effect of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr on other electrocardiogram (ECG) parameters.

    Number of participants with changes in PR interval from baseline.

    Time frame: Pre-dose through 24 hours post-dose

  4. 1. To evaluate the effect of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr on other electrocardiogram (ECG) parameters.

    Number of participants with changes in RR interval from baseline.

    Time frame: Pre-dose through 24 hours post-dose

  5. 1. To evaluate the effect of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr on other electrocardiogram (ECG) parameters.

    Number of participants with changes in QRS duration from baseline.

    Time frame: Pre-dose through 24 hours post-dose

  6. 1. To evaluate the effect of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr on other electrocardiogram (ECG) parameters.

    Number of participants with changes in heart rate (HR) from baseline.

    Time frame: Pre-dose through 24 hours post-dose

  7. 2. To evaluate pharmacokinetics (PK) of tebipenem (TBPM) after administration of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr.

    AUC0-last will be calculated for TBPM and moxifloxacin in plasma.

    Time frame: Pre-dose through 24 hours post-dose

  8. 2. To evaluate pharmacokinetics (PK) of tebipenem (TBPM) after administration of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr.

    AUC0-inf will be calculated for TBPM and moxifloxacin in plasma.

    Time frame: Pre-dose through 24 hours post-dose

  9. 2. To evaluate pharmacokinetics (PK) of tebipenem (TBPM) after administration of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr.

    AUC%extrap will be calculated for TBPM and moxifloxacin in plasma.

    Time frame: Pre-dose through 24 hours post-dose

  10. 2. To evaluate pharmacokinetics (PK) of tebipenem (TBPM) after administration of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr.

    Cmax will be calculated for TBPM and moxifloxacin in plasma.

    Time frame: Pre-dose through 24 hours post-dose

  11. 2. To evaluate pharmacokinetics (PK) of tebipenem (TBPM) after administration of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr.

    Tmax will be calculated for TBPM and moxifloxacin in plasma.

    Time frame: Pre-dose through 24 hours post-dose

  12. 2. To evaluate pharmacokinetics (PK) of tebipenem (TBPM) after administration of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr.

    Kel will be calculated for TBPM and moxifloxacin in plasma.

    Time frame: Pre-dose through 24 hours post-dose

  13. 2. To evaluate pharmacokinetics (PK) of tebipenem (TBPM) after administration of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr.

    t1/2 will be calculated for TBPM and moxifloxacin in plasma.

    Time frame: Pre-dose through 24 hours post-dose

  14. 3. To assess the safety and tolerability of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr.

    Number of participants with treatment-related adverse events using CTCAE v5.0.

    Time frame: Pre-dose through 24 hours post-dose

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Feb 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2020
First posted
Jan 23, 2020
StartActual
Jan 19, 2020
Primary completionActual
Feb 26, 2020
CompletionActual
Feb 26, 2020
Last update
Mar 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04238195
Lead sponsor
Spero Therapeutics
Collaborators
Celerion
Responsible party
Sponsor
First posted
Jan 23, 2020
Start date
Jan 19, 2020
Primary completion
Feb 26, 2020
Completion
Feb 26, 2020
Last update
Mar 13, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tebipenem

Start the discussion